Schirmeister T - Search Results

1

Aziridine-2,3-dicarboxylates, peptidomimetic cysteine protease inhibitors with antileishmanial activity.

Ponte-Sucre A, Vicik R, Schultheis M, Schirmeister T, Moll H. Ponte-Sucre A, et al. Among authors: schirmeister t. Antimicrob Agents Chemother. 2006 Jul;50(7):2439-47. doi: 10.1128/AAC.01430-05. Antimicrob Agents Chemother. 2006. PMID: 16801424 Free PMC article.

2

Synthesis and antiplasmodial activity of a cysteine protease-inhibiting biotinylated aziridine-2,3-dicarboxylate.

Gelhaus C, Vicik R, Hilgenfeld R, Schmidt CL, Leippe M, Schirmeister T. Gelhaus C, et al. Among authors: schirmeister t. Biol Chem. 2004 May;385(5):435-8. doi: 10.1515/BC.2004.050. Biol Chem. 2004. PMID: 15196005

3

Blocking effect of a biotinylated protease inhibitor on the egress of Plasmodium falciparum merozoites from infected red blood cells.

Gelhaus C, Vicik R, Schirmeister T, Leippe M. Gelhaus C, et al. Among authors: schirmeister t. Biol Chem. 2005 May;386(5):499-502. doi: 10.1515/BC.2005.059. Biol Chem. 2005. PMID: 15927894

4

Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor.

Martina E, Stiefl N, Degel B, Schulz F, Breuning A, Schiller M, Vicik R, Baumann K, Ziebuhr J, Schirmeister T. Martina E, et al. Among authors: schirmeister t. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5365-9. doi: 10.1016/j.bmcl.2005.09.012. Epub 2005 Oct 10. Bioorg Med Chem Lett. 2005. PMID: 16216498 Free PMC article.

5

A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods.

Kaeppler U, Stiefl N, Schiller M, Vicik R, Breuning A, Schmitz W, Rupprecht D, Schmuck C, Baumann K, Ziebuhr J, Schirmeister T. Kaeppler U, et al. Among authors: schirmeister t. J Med Chem. 2005 Nov 3;48(22):6832-42. doi: 10.1021/jm0501782. J Med Chem. 2005. PMID: 16250642

6

Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents.

Vicik R, Hoerr V, Glaser M, Schultheis M, Hansell E, McKerrow JH, Holzgrabe U, Caffrey CR, Ponte-Sucre A, Moll H, Stich A, Schirmeister T. Vicik R, et al. Among authors: schirmeister t. Bioorg Med Chem Lett. 2006 May 15;16(10):2753-7. doi: 10.1016/j.bmcl.2006.02.026. Epub 2006 Mar 3. Bioorg Med Chem Lett. 2006. PMID: 16516467

7

Inhibitors of cysteine proteases.

Vicik R, Busemann M, Baumann K, Schirmeister T. Vicik R, et al. Among authors: schirmeister t. Curr Top Med Chem. 2006;6(4):331-53. doi: 10.2174/156802606776287081. Curr Top Med Chem. 2006. PMID: 16611146 Review.

8

Rational design of aziridine-containing cysteine protease inhibitors with improved potency: studies on inhibition mechanism.

Vicik R, Helten H, Schirmeister T, Engels B. Vicik R, et al. Among authors: schirmeister t. ChemMedChem. 2006 Sep;1(9):1021-8. doi: 10.1002/cmdc.200600081. ChemMedChem. 2006. PMID: 16933238

9

Aziridide-based inhibitors of cathepsin L: synthesis, inhibition activity, and docking studies.

Vicik R, Busemann M, Gelhaus C, Stiefl N, Scheiber J, Schmitz W, Schulz F, Mladenovic M, Engels B, Leippe M, Baumann K, Schirmeister T. Vicik R, et al. Among authors: schirmeister t. ChemMedChem. 2006 Oct;1(10):1126-41. doi: 10.1002/cmdc.200600106. ChemMedChem. 2006. PMID: 16933358

10

The importance of the active site histidine for the activity of epoxide- or aziridine-based inhibitors of cysteine proteases.

Mladenovic M, Schirmeister T, Thiel S, Thiel W, Engels B. Mladenovic M, et al. Among authors: schirmeister t. ChemMedChem. 2007 Jan;2(1):120-8. doi: 10.1002/cmdc.200600159. ChemMedChem. 2007. PMID: 17066390

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

198 results

Search Page